Ibandronate: The Evolution of a Once-a-Month Oral Therapy for Postmenopausal Osteoporosis

Journal of Clinical Densitometry

Volumn 9, Issue 1, 2006, Pages 58-65

  Dempster, David W ^a   Bolognese, Michael A ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Bethesda Health Research   (United States)

Author keywords

Adherence; bisphosphonates; ibandronate; osteoporosis; postmenopause

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; EB 1053; ETIDRONIC ACID; IBANDRONIC ACID; MINODRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; CHRONICITY; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; OSTEOCLAST; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION; VERTEBRA FRACTURE;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE;

EID: 33646826836     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2005.09.004     Document Type: Article

References (62)

1. Siris ES, Rosen CJ, Harris ST, Abbott TA III, Barr CE, Silverman SL. 2005 Adherence rates to bisphosphonate therapy: relationship to bone fractures at 24 months in women with postmenopausal osteoporosis. Proc 6th International Symposium on Osteoporosis: Current Status and Future Directions, the National Osteoporosis Foundation, Washington, DC, 2005.
2. US Department of Health and Human Services. 2004 Bone health and osteoporosis: a report of the Surgeon General (2004). Available at: http://www.hhs.gov/surgeongeneral/library/bonehealth/content.html. Accessed April 6, 2005.
3. Body J.J. Management of primary osteoporosis. Acta Clin Belg 57 (2002) 277-283
4. National Osteoporosis Foundation. 2004 Osteoporosis fast facts. Available at: http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed February 7, 2005.
5. Melton III L.J. How many women have osteoporosis now?. J Bone Miner Res 10 (1995) 175-177
6. Cooper C. 1996 Epidemiology and Definition of Osteoporosis. In: Osteoporosis: New Perspectives on Causes, Prevention, and Treatment. Compston JE, ed. Royal College of Physicians, London, 1-10.
7. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. 1998 Osteoporos Int 8(Suppl 4):S7-S80.
8. Kessel B. Hip fracture prevention in postmenopausal women. Obstet Gynecol Surv 59 (2004) 446-455
9. Kado D.M., Browner W.S., Palermo L., Nevitt M.C., Genant H.K., Cummings S.R., and for the Study of Osteoporotic Fractures Research Group. Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med 159 (1999) 1215-1220
10. Barrett-Connor E. The economic and human costs of osteoporotic fracture. Am J Med 98 Suppl 2A (1995) 3S-8S
11. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebal fractures. Lancet 348 (1996) 1535-1541
12. ® International Trial Study Group. Osteoporos Int 9 (1999) 461-468
13. Reginster J.-Y., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 (2000) 83-91
14. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
15. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
16. Hulley S., Grady D., Bush T., et al., for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
17. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (2002) 49-57
18. Recker R.R., Gallagher R., and MacCosbe P.E. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80 (2005) 856-861
19. McCombs J.S., Thiebaud P., McLaughlin-Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
20. Caro J.J., Ishak K.J., Huybrechts K.F., Raggio G., and Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15 (2004) 1003-1008
21. Harris ST, Siris E, Abbott TA, Barr CE, Rosen CJ. 2005 Reduced osteoporotic fracture risk in patients adherent to bisphosphonate therapy. Proc ENDO 2005 Annual Meeting, San Diego, CA, 2005.
22. Gupta A.K., Dlova N., Taborda P., et al. Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study. Br J Dermatol 142 (2000) 965-968
23. Miner C.M., Brown E.B., Gonzales J.S., and Munir R. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. J Clin Psychiatry 63 (2002) 232-240
24. Moller H.J., Llorca P.M., Sacchetti E., et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 20 (2005) 121-130
25. Archer D.F., Cullins V., Creasy G.W., and Fisher A.C. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception 69 (2004) 189-195
26. Miller P.D., McClung M.R., Macovei L., et al. Monthly oral ibandronate in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20 (2005) 1315-1322
27. Biskobing D.M. Novel therapies for osteoporosis. Expert Opin Investig Drugs 12 (2003) 611-621
28. Papapoulos S.E. Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis. Int J Clin Pract 57 (2003) 417-422
29. Body J.J. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 28 (2001) 49-53
30. Negri A.J. Short-term compliance with alendronate 70 mg in patients with osteoporosis: the ECMO trial. Bone 25 5 Suppl (2003) S209
31. Simon J.A., Lewiecki E.M., Smith M.E., Petruschke R.A., Wang L., and Palmisano J.J. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24 (2002) 1871-1886
32. Hodsman A., Adachi J., and Olszynski W. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis. CMAJ 155 (1996) 945-948
33. Russell R.G., and Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25 (1999) 97-106
34. Bell N.H., and Johnson R.H. Bisphosphonates in the treatment of osteoporosis. Endocrine 6 (1997) 203-206
35. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9 (2003) 2643-2658
36. Frith J.C., and Rogers M.J. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 18 (2003) 204-212
37. Dunford J.E., Thompson K., Coxon F.P., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296 (2001) 235-242
38. Mühlbauer R.C., Bauss F., Schenk R., et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6 (1991) 1003-1011
39. Bauss F., and Russell R.G. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 15 (2004) 423-433
40. Schimmer R.C., and Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther 25 (2003) 19-34
41. Chesnut C.H., Ettinger M.P., Miller P.D., et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 21 (2005) 391-401
42. Delmas P.D., Recker R.R., Chesnut III C.H., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15 (2004) 792-798
43. Chesnut III C.H., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
44. Barrett J., Worth E., Bauss F., and Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44 (2004) 951-965
45. ®(ibandronate sodium) tablets. [package insert] (2005), Roche Laboratories Inc., Nutley, NJ
46. Bauss F., Wagner M., and Hothorn L.H. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol 29 (2002) 990-998
47. Bauss F., Lalla S., Endele R., and Hothorn L.A. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 29 (2002) 2200-2208
48. Lalla S., Hothorn L.A., Haag N., Bader R., and Bauss F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos Int 8 (1998) 97-103
49. Pfister T., Atzpodien E., and Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 191 (2003) 159-167
50. Monier-Faugere M.C., Geng Z., Paschalis E.P., et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 14 (1999) 1768-1778
51. Smith S.Y., Recker R.R., Hannan M., Muller R., and Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32 (2003) 45-55
52. Muller R., Hannan M., Smith S.Y., and Bauss F. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res 19 (2004) 1787-1796
53. Bauss F., Schenk R.K., Hort S., Muller-Beckmann B., and Sponer G. New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods 50 (2004) 25-34
54. Tanko L.B., Mouritzen U., Lehmann H.J., et al. Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone 32 (2003) 687-693
55. Sartori L., Adami S., Filipponi P., and Crepaldi G. Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. Aging Clin Exp Res 15 (2003) 271-283
56. Adami S., Felsenberg D., Christiansen C., et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34 (2004) 881-889
57. Thiebaud D., Burckhardt P., Kriegbaum H., et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103 (1997) 298-307
58. Stakkestad J.A., Benevolenskaya L.I., Stepan J.J., et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 62 (2003) 969-975
59. Recker R., Stakkestad J.A., Chesnut III C.H., et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34 (2004) 890-899
60. Riis B.J., Ise J., von Stein T., Bagger Y., and Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16 (2001) 1871-1878
61. Cooper C., Emkey R.D., McDonald R.H., et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88 (2003) 4609-4615
62. Tanko L.B., Felsenberg D., Czerwinski E., et al. Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med 254 (2003) 159-167